Aggregation-Disruption-Induced Multi-Scale Mediating Strategy for Anticoagulation in Blood-Contacting Devices
Mingfei Pan1,2, Zhaoyun Sun3, Yuhao Zhang4
1Key Laboratory for Bio-Electromagnetic Environment and Advanced Medical Theranostics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, 211166, China.
Advanced Materials (Deerfield Beach, Fla.)
|September 30, 2024
Summary
Minimally invasive devices can cause dangerous blood clots. This study developed a new coating that prevents clot formation by inhibiting coagulation factors and resisting cell aggregation, offering a long-term solution.
Area of Science:
- Biomaterials Science
- Cardiovascular Research
- Hemostasis and Thrombosis
Background:
- Minimally invasive blood-contacting devices are crucial for cardiovascular disease treatment.
- Device-related thrombosis, especially cycling thrombi, presents a significant life-threatening risk.
- Understanding initial coagulation contact activation on device surfaces is vital for prevention.
Purpose of the Study:
- To investigate the initial stages of coagulation contact activation on extrinsic surfaces of blood-contacting devices.
- To develop an advanced coating strategy for long-term anticoagulation.
- To mitigate the risk of device-related thrombosis.
Main Methods:
- Direct force measurements to analyze coagulation factor interactions.
- Ex vivo coagulation tests to assess fibrin aggregation inhibition.
- Development of an engineered serum protein coating with zwitterion grafts and protease inhibitor coacervates.
Main Results:
- Activated contact factors stimulate the intrinsic coagulation pathway and fibrin crosslinking.
- Surface-grafted inhibitors effectively disrupt fibrin aggregation.
- The engineered coating resists biological deposition and inhibits coagulation pathways.
- The coating demonstrates material regeneration capabilities.
Conclusions:
- A novel multi-scale mediation strategy effectively inhibits nanoscale coagulation factors.
- The developed coating resists microscale thrombus aggregation, providing a long-term anticoagulation solution.
- This approach offers significant potential for improving the safety of blood-contacting interventional devices.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
636
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
636
01:29Venous Thrombosis III: Interprofessional Care
3
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
3
01:16Clot Retraction and Fibrinolysis
4.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.7K
01:05Introduction to Hemostasis
6.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
6.4K
01:24Disorders of Hemostasis
738
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
738
01:06Coagulation
274
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
274